Schering Corporation

Pradeep B Pushpavanam

John W Clader

Anandan Palani

Hubert B Josien

Susan F Vice

Thomas A Bara

Shengjian Li

Mark D McBriar

Sherry A Shapiro

Stuart W Mc Combie

Sue-Ing Y Lin

The present invention discloses methods of using antagonists for melanin-concentrating hormone (MCH), to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes, as well as novel compounds which are antagonists for melanin-concentrating hormone (MCH). In other aspects, the invention is directed to pharmaceutical compositions comprising such MCH antagonists as well as methods for preparing such compounds. Compounds of the invention generally have the structure: where the substituents are as defined herein.

MCH antagonists for the treatment of obesity

In one embodiment, this invention provides a novel class of aryl oxime-piperazine compounds as antagonists of the CCR5 receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more of the compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention or amelioration of one or more of diseases associated with the CCR5 receptor. An illustrative inventive compound is shown below:

Aryl oxime-piperazines useful as CCR5 antagonists

Growing community of inventors

Kendall Park, NJ, United States of America

Pradeep B Pushpavanam